Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 8/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.39 |
| ▸ | AURKA | O14965 | 4/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6428505 | 0.94 | ROCK2 (0.40) | MAPK1ROCK2ROCK1AURKAAURKB | |
| SCHEMBL6425756 | 0.94 | MAPK1 (0.43) | MAPK1ROCK2ROCK1AURKAAURKB | |
| SCHEMBL5034325 | 0.92 | MAPK1 (0.43) | MAPK1ROCK2ROCK1AURKAAURKB | |
| SCHEMBL13927708 | 0.92 | MAPK1 (0.43) | MAPK1ROCK2ROCK1AURKAAURKB | |
| SCHEMBL6444320 | 0.92 | MAPK1 (0.38) | MAPK1ROCK2ROCK1AURKAAURKB | |
| SCHEMBL6444327 | 0.92 | MAPK1 (0.38) | MAPK1ROCK2ROCK1AURKAAURKB | |
| SCHEMBL6428666 | 0.92 | MAPK1 (0.38) | MAPK1ROCK2ROCK1AURKAAURKB | |
| SCHEMBL6428432 | 0.91 | ROCK2 (0.47) | MAPK1ROCK2ROCK1AURKAAURKB | |
| SCHEMBL6428627 | 0.91 | MAPK1 (0.41) | MAPK1ROCK2ROCK1AURKAADORA2A | |
| SCHEMBL5029946 | 0.90 | ROCK1 (0.42) | MAPK1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | MAPK1 7/4885ROCK2 503/4885ROCK1 768/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | MAPK1 6/4885ROCK2 560/4885ROCK1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.